ATE384793T1 - Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen - Google Patents

Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen

Info

Publication number
ATE384793T1
ATE384793T1 AT00962125T AT00962125T ATE384793T1 AT E384793 T1 ATE384793 T1 AT E384793T1 AT 00962125 T AT00962125 T AT 00962125T AT 00962125 T AT00962125 T AT 00962125T AT E384793 T1 ATE384793 T1 AT E384793T1
Authority
AT
Austria
Prior art keywords
dna fragments
corresponding dna
chlamydia antigens
chlamydia
strain
Prior art date
Application number
AT00962125T
Other languages
German (de)
English (en)
Inventor
Andrew Murdin
Raymond Oomen
Joe Wang
Pamela Dunn
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE384793T1 publication Critical patent/ATE384793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00962125T 1999-09-20 2000-09-15 Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen ATE384793T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15465299P 1999-09-20 1999-09-20

Publications (1)

Publication Number Publication Date
ATE384793T1 true ATE384793T1 (de) 2008-02-15

Family

ID=22552195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962125T ATE384793T1 (de) 1999-09-20 2000-09-15 Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen

Country Status (9)

Country Link
US (2) US7314869B2 (https=)
EP (1) EP1220925B8 (https=)
JP (1) JP4667694B2 (https=)
AT (1) ATE384793T1 (https=)
AU (1) AU783547B2 (https=)
CA (1) CA2385325C (https=)
DE (1) DE60037900T2 (https=)
NZ (1) NZ517952A (https=)
WO (1) WO2001021804A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
EP1105489A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2353107A1 (en) 1998-12-01 2000-06-08 Andrew D. Murdin Chlamydia antigens and corresponding dna fragments and uses thereof
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
MXPA01009256A (es) 1999-03-12 2003-07-14 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化
EP1687430A4 (en) * 2003-11-21 2007-05-02 Sanofi Pasteur Ltd IMMUNIZATION AGAINST CHLAMYDIA INFECTION
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312920T1 (de) 1996-07-12 2005-12-15 Dna immunisierung gegen chlamydia infektion
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
JP4160640B2 (ja) * 1997-06-23 2008-10-01 スヴェンド バークランド クラミジア・ニューモニエ由来の表面露出タンパク質
DE69841894D1 (de) * 1997-11-21 2010-10-21 Merck Serono Biodevelopment Sa Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
JP2002536958A (ja) * 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
EP2218731A1 (en) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
WO2000011181A1 (en) * 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) * 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
MXPA01004291A (es) 1998-10-28 2003-06-09 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
CA2353107A1 (en) * 1998-12-01 2000-06-08 Andrew D. Murdin Chlamydia antigens and corresponding dna fragments and uses thereof
JP2002531129A (ja) 1998-12-08 2002-09-24 コリクサ コーポレイション クラミジア感染の処置および診断のための化合物および方法
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6808713B1 (en) * 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
DE60036698T2 (de) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU2138501A (en) * 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20030100706A1 (en) * 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) * 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (ja) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化

Also Published As

Publication number Publication date
DE60037900T2 (de) 2009-02-12
CA2385325A1 (en) 2001-03-29
EP1220925B8 (en) 2008-04-23
JP4667694B2 (ja) 2011-04-13
US7314869B2 (en) 2008-01-01
AU783547B2 (en) 2005-11-10
WO2001021804A1 (en) 2001-03-29
EP1220925B1 (en) 2008-01-23
EP1220925A1 (en) 2002-07-10
NZ517952A (en) 2004-01-30
AU7398500A (en) 2001-04-24
WO2001021804B1 (en) 2001-05-10
US20050220805A1 (en) 2005-10-06
CA2385325C (en) 2012-04-10
JP2003510050A (ja) 2003-03-18
US20050002944A1 (en) 2005-01-06
US7662391B2 (en) 2010-02-16
DE60037900D1 (de) 2008-03-13

Similar Documents

Publication Publication Date Title
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
ATE463575T1 (de) Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
ATE542829T1 (de) Impfstoff
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
CY1108106T1 (el) Χειμερικα μορια l1 ανθρωπινου θηλωματοϊου (hpv) και χρησεις τους
WO2003049762A3 (en) Immunisation against chlamydia trachomatis
ATE325620T1 (de) Streptococcus pneumoniae proteine und impfstoffe
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DE60120621D1 (de) Lawsonia intracellularis Impfstoff
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
DE60336927D1 (https=)
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
SE9903534D0 (sv) Vaccin
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
WO2005048918A3 (en) Anthrax vaccine
DK1227840T3 (da) Adjuverede, genetiske vacciner
WO2004073604A3 (en) Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
WO2001036455A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2000006743A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001036457A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO1998046742A3 (de) Dictyocaulus viviparus antigen zur diagnose des lungenwurmbefalls und zur vakzinierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1220925

Country of ref document: EP